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1. GENERAL INTRODUCTION
1.1 OVERVIEW
Ischaemia-reperfusion injury refers to injury that occurs in cells or tissues when the particular tissue
region/organ is subjected to a prolonged period of oxygen deprivation (ischaemia), followed by immediate
reoxygenation (reperfusion). It has been well documented that prolonged ischaemia is capable of causing cell
swelling, vasoconstriction and rapid tissue necrosis (Thadani et.al., 1996). In many instances, prompt
reperfusion to the affected tissue region remains the only choice for restoration, repair and regeneration of
tissue structure and function. Nevertheless, although reperfusion, by definition, relieves or at least reduces
ischaemia, it often initiates a complex series of phenomena which may further aggravate the tissue injury and
minimize the chances of the affected tissue/organ to full recovery (Braunwald & Kloner, 1985).
The deleterious effects of the ischaemia-reperfusion injury can be clearly observed in the human
cardiovascular diseases and organ transplant related complications. Cardiovascular diseases have long been
one of the major public health threats in the world population. Various studies have shown that the initiation
and complication of many types of acute cardiovascular diseases, including acute myocardial infarct,
ischaemic acute renal failure, aortic-cross clamping event, etc. have been associated with ischaemia-
reperfusion injury (Sheridan et.al" 1996, Thadani et.al., 1996, Weight et.al., 1996) On the other hand, organ
transplantation (e.g. heart and kidney transplantation) is also made difficult as the ischaemia-reperfusion
injury that is prone to develop in the transplanted organs (which is promptly reperfused after a substantial
period of oxygen deprivation) often accelerates graft rejection (Post & Messmer, 1996, Dragun et.al., 1998)
In recent years, the significance of the ischaemia-reperfusion injury in the development of the
cardiovascular disease and graft rejection has begun to be noticed by the research community. In response,
many new strategies have been proposed in an attempt to ameliorate ischaemia-reperfusion injury, and
among those that have potential in yielding promising results is the short term genetic therapy.
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In recent times, the application of short term gene therapy, i.e. utilization of the antisense
technology in ameliorating the renal ischaemia-reperfusion injury has been reported to be successful in a rat
model of renal ischaemia, whereby the immunohistochemical assessments have shown that the ischaemic
kidney is well protected from deleterious reperfusion 'damage'(Haller et.al., 1996). This study has given rise
to a promising future in reapplying the antisense technology in ameliorating the ischaemia-reperfusion injury
in other models of acute cardiovascular diseases (especially in acute myocardial infarction) and also in organ
transplantation. Nevertheless, the physiological significance of the antisense gene therapy has yet to be
confirmed as preservation in tissue histology does not necessarily guarantee the integrity of the physiology
and function of the affected body system.
Thus, the present research sets out to examine the impact of the antisense gene therapy on the
physiology of the ischaemic insulted cardiovascular sub-system. For this purpose, the ischaemia-reperfusion
injury model in renal vascular system was selected for the following reasons:
The kidney plays a crucial role in cardiovascular and fluid-electrolyte homeostasis
(Vander, 1995)
Ischaemic acute renal failure is often found to be developed in hospitalized patients,
especially among the myocardial infarct, cardiac and the renal transplant patients.
The major component of the antisense therapy, the antisense oligodeoxynuc1eotides can
be effectively taken up by kidney tissue (Agrawal et.al., 1995)
A treatment model that is developed against renal ischaemic reperfusion injury can be
potentially reapplied in other cardiovascular subsystems.
The present study would generate useful physiological data that would give rise to further
understanding of the underlying mechanisms of the ischaemia-reperfusion injury as well as the amelioration
process of the antisense gene therapy.
.\
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2. MATERIALS AND METHODS
2.1 Introduction
In order to obtain useful data systematically, the study has been designed to look at the various physiological
parameters to assess the Lipofectin- As-ODN mediated amelioration of rat renal ischaemia-reperfusion injury
In each phase of the study, a standardized set of experiments was performed so as to accumulate
sufficient data for the evaluation of the ameliorative effects of As-ODN over the renal ischaemia-reperfusion
injury in different conditions. The type and the interrelation of these experiments are as shown in figure
2.1A.
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Figure 2.1A: Standardized study outline
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From these experiments, data for the following parameters (Table 2.1 a) was obtained:
Table 2.1a Experimental parameters
Type of experiment Parameter
1. Acute study Urine flow rate ().1lmin-1 kg-I)
Arterial blood pressure (mmHg)
Renal blood flow (ml min- l kg-I)
2. Electrolyte assay Urine'Na+ concentration ().1moIL·1)
Plasma Na+ concentration (mmoIL'I)
3. Inulin assay Urine inulin concentration (mg mr )
Plasma inulin concentration (mg mr l )
4, Physiological data analysis Inulin clearance/ glomerular filtration rate (mlmin- kg' )
Plasma Na+ concentration (mmoIL'I)
Absolute Na+ excretion ().1molmin,1 kg'l)
Fractional Na+ excretion (%)
S. TTi~tologi~.1I1 5tllJy RCllal ti!iwC damage l1ssessment
6. Western analysis (with help of Renal tissue ICAM-l expression (intensity mm-)
densitometry method)
3. Evaluation of the Lipofectin-As-ODN Mediated Amelioration of Rat Renal Ischaemia-
Reperfusion Injury
In this study, the As-ODN molecule for ICAM-l was introduced intravenously (with lipofectin as
the ODN carrier) to the rat with a renal ischaemia-reperfusion injury model as developed in our laboratory.
The study sets out to assess the significance of the As-ODN's ameliorative effects over the initial post
ischaemia renal haemodynamic and functional distortion, while at the same time providing further evidence
for the role played by the ICAM-l upregulation in the development of ischaemia reperfusion injury. It was
also the aim to investigate the possible adverse effects to the renal haemodynamics and function due to the
use of lipofectin.
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The whole study was divided into 3 parts. In each part, the changes in renal physiology as well as
ICAM-l expression in the experimental groups were documented along the first 3 hrs post ischaemia. As for
histological evaluation, the renal tissue samples collected from respective sub-phase experiments in Phase 2
were processed and analyzed together, and the results were reported. The REF (ml/min/kg), GFR (mlmin-'
kg-I), PNa (mmoIL-') and AbsNa (I-lmolmin- I kg-I) values were further normalized and converted into
percentage of baseline to eliminate basal differences due to biological variations, in order to perform
comparison in between groups impartially. The original values for arterial blood pressure (ABP, mmHg),
urine flow rate (UFR, mlmin- I kg-I) and fractional sodium excretion (FENa, %) were kept and analyzed, as
no significant difference was found in between these baseline values. The details of these changes as well as
their significance were recorded and discussed, as shown below.
3.1: Part 1
In the first part, preliminary trials using the As-ODN mediated ischaemia-reperfusion injury
treatment model suggested by Haller et at. (1996) were performed so as to observe any possible improvement
in post ischaemia renal physiology. At the same time, the time-frame of the As-ODN administration prior to
the ischaemia-reperfusion insult was tested so as to determine the optimal time period needed for the
administered As-ODN to enter the renal cells and exert its action.
In the study, two As-ODN administration times were selected, i.e. 6 hr prior to ischaemia (rat group:
A6, n=6) and 8 hr prior to ischaemia (rat group: A8, n=6). The As-OD was administered in the presence of
the transfecting agent lipofectin.
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3.2. Renal Physiological Changes
The basal levels of arterial blood pressure, renal haemodynamic and excretory variables of the Ie,
Tm, A6 and A8 groups are listed in Table 3.2a .
Table 3.2a Baseline values for all physiological variables assessed (Phase 2.1 study)
Groups Ic (n=6) Tm (n=6) A6 (n=6) A8 (n=6)
Mean Value Standard Mean Value Standard Mean Value Standard Mean Value Standard
Error (±) Error (±) Error (±) Error (±)
Arterial Blood Pressure (mmHg)
123 3.10 122 2.60 123 4.01 122 3.83
Renal Blood Flow
(mlmin,1 kg'l) 10.84 0.55 11.24 l.l5 8.64 0.46 8.09 0.47
Glomerular Filtration Rate (mlmin'
kg,l) 2.75 0.15 2.25 0.21 1.99 0.26 2.28 0.29
Urine Flow Rate
(/llmin,1 kg,l) 21.97 l.l9 23.62 2.57 19.74 3.65 19.71 4.62
Plasma Sodium
(mmoIL'I) 161.85 2.51 167.00 4.65 159.50 2.82 155.88 7.92
Absolute Sodium Excretion (/lmolmin'
1 kg'l) 2.49 0.40 3.34 0.79 4.34 1.27 3.51 1.97
Fractional Sodium Excretion (%)
0.71 0.12 0.90 0.22 0.69 0.33 0.68 0.44
3.3. Mean Arterial Blood Pressure
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Figure 3.3.IA: Mean Arterial blood pressure (ABP)
The figure shows the mean arterial blood pressure (± SEM) of the Ic group (rats received 30min of renal
ischaemia, n=6), Tm group (rats that did not received renal ischaemia, n=6), A6 group (rats received As-
OON [2mglkg rat] + lipofectin [O.8mglmg OON] 6hrs prior to 30min renal ischaemia, n=6) and A8 group
(rats received As-OON [2mglkg rat] + lipofectin [O.8mglmg OON] 8hrs prior to 30min renal ischaemia,
n=6) throughout the study.
In the study, the ASP (in terms of mmHg) for the A6 and A8 group was unchanged by the
ischaemic challenge and remain stable within physiological range throughout the period of observation
(Figure 3.3.1 A). No significant difference was found in between the ASP patterns of these groups or with
those of the Ie as well as the Tm group.
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3.4. Renal Blood Flow
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Figure 3.4.1A: Renal blood flow (RBF)
The figure shows the renal blood flow (mean ± SEM) of the Ie group (rats received 30min of renal
ischaemia, n=6), Tm group (rats that did not received renal ischaemia, n=6), A6 group (rats received As-
OON [2mg/kg rat] + lipofectin [0.8mgimg OON] 6hrs prior to 3'Omin renal ischaemia, n=6) and A8 group
(rats received As-OON [2mg/kg rat] + lipofectin [0.8mg/mg 00 ] 8hrs prior to 30min renal ischaemia,
n=6) throughout the study.
Similar to the lc group, the renal blood flow (%) of the A6 and A8 dropped to 0% from baseline
value (100%) upon initiation of renal ischaemia (Figure 3.4.1A). Once renal blood supply was restored, the
RBF of the A8 group was found gradually recovered from about 60% (at the initiation of reperfusion) to
approximately 80% of baseline value (at the end of study, p<O.OOI), a level which resembled that of the Ie
group post ischaemia REF level. As for the A6 group, RBF recovered only to about 50% of baseline
(p<O.OO 1 compared to baseline, and p<0.05 compare to A8) and persisted at the same level throughout the
·1
3hr reperfusion period. RBF for the Tm group remained stable throughout the study and was used as a basal
guideline in the present comparison of results.
3.5 Glomerular Filtration Rate
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Figure 3.5.1A: Glomerular filtration rate (GFR)
The figure shows the glomerular filtration rate (mean ± SEM) of the Ic group (rats received 30min of renal
ischaemia, n=6), Tm group (rats that did not receive renal ischaemia, n=6), A6 group (rats received As-
ODN [2mg/kg rat] + lipofectin [0.8mg/mg ODN] 6hrs prior to 30min renal ischaemia, n=6) and A8 group
(rats received As-ODN [2mg/kg rat] + lipofectin [0.8mg/mg ODN] 8hrs prior to 30min renal ischaemia,
n=6) throughout the study.
In the study, GFR for the Tm group was used as the basal level reference. From figure 3.5.1 A, it
can be seen that the GFR of A6 and A8 group fell to 0% from baseline (100%) when ischaemia was
initiated. When renal reperfusion began, both A6 and A8 group exhibited a slow recovery in GFR (10% of
basal level, compared to 60% GFR recovery in Ic group) in the first 15 min of reperfusion. Nevertheless, a
rapid rise could be observed in the GFR of the A6 group in the subsequent 45 minutes, i.e. from 10% of
basal level to 20% above basal level (p<0.05). The trend of A6's GFR increase resembled those of the Ic
group (p > 0.05). The marked rise in GFR of A6 persisted til.! the end of study. On the other hand, the GFR
of the A8 group gradually recovered back to near basal level over the 3hr reperfusion period.
3.6 Urine Flow Rate
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Figure 3..6.tA Urine Flow Rate (UFR)
The figure shows the urine flow rate (mean ± SEM) of Ie group (rats received 30min of renal ischaemia,
n=6), Tm group (rats that did not receive renal ischaemia, n=6), A6 group (rats received As-OD [2mg/kg
rat] + lipofectin [0.8mg/mg ODN] 6hrs prior to 30min renal ischaemia, n=6) and A8 group (rats received
As-ODN [2mglkg rat] + lipofectin [0.8mg/mg ODN] 8hrs prior to 30min renal ischaemia, n=6) throughout
the study.
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In the study, both A6 and A8 groups exhibited different UFR patterns compared to the Ie group,
although all these groups underwent similar period of ischaemia. From figure 3.6.IA, it was observed that
the A6 group showed a significant post ischaemic lise in UFR (~.dmin-l kg-I) compared to baseline and the
A8 group (i.e. from 0 mlmin- I kg- 1 during ischaemia to some 2-fold of baseline during reperfusion, p<0.05).
The trend of increase resembled that of the Ie group (p>0.05), whereas for A8 group, the UFR that was
depressed for the first 15 min ofreperfusion but recovered back to basal value at the 30 minutes time point
of reperfusion. Subsequently, UFR remained close to baseline till the end of the study. No significant
difference was found between the UFR of the A8 and Tm group (which was used as the baseline reference
in the study).
3.7 Plasma sodium concentration, absolute sodium excretion and fractional sodium excretion
Similar to the; UfR re:iults. the AR vmllp shnwr.rl nn "ienifir,;mt rlifft'Tt"nrt"~ in PNl1, Ah~Nl1 1111li
FENa compared to baseline and the Tm group throughout the reperfusion period, indicating general
recovery of renal tubular reabsorption function after ischaemia. Nevertheless, the AbsNa and FENa for the
A6 group were increased significantly from baseline during reperfusion (i.e. to about 13 folds for AbsNa,
and 5 folds for FENa, both levels resembling that of the Ic group [p>0.05]) in the prese,nce of normal PNa
values. The pattern of elevated levels of absolute sodium excretion and FENa in the A6 groups persisted till
the end of the study.
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Figure 3.7.1A Plasma sodium concentration (PNa)
The figure shows the plasma sodium concentration (mean ±SEM) of the lc group (rats received 30min of
renal ischaemia, n=6), Tm group (rats that did not received renal ischaemia, n=6), A6 group (rats received
As-ODN [2mglkg rat] + lipofectin [O.8mglmg ODN] 6hrs prior to 30min renal ischaemia, n=6) and A8
group (rats received As-ODN [2mglkg rat) + lipofectin [O.8mglmg ODN) 8hrs prior to 30min renal
ischaemia, n=6) throughout the study.
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Figure :'L7.1 H: Absolute sodium excretion (AbsNa)
The figure shows the absolute sodium excretion (mean ±SEM) of the Ic group (rats received 30min of
renal ischaemia, n=6), Tm group (rats that did not receive renal ischaemia, n=6), A6 group (rats received
As-OON [2mg/kg rat] + lipofectin [O.8mg/mg OON] 6hrs prior to 30min renal ischaemia, n=6) and A8
group (rats received As-OON [2mg/kg rat] + lipofectin [O.8mg/mg OON] 8hrs prior to 30min renal
ischaemia, n=6) throughout the study.
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Fi~ure 3..7.1C: Fractional sodium excretion (FE a)
The figure shows the fractional sodium excretion (mean ± SEM) of the Ie group (rats received 30min of
renal ischaemia, n=6), Tm group (rats that did not receive renal ischaemia, n=6), A6 group (rats received
As-ODN [2mg/kg rat] + lipofectin [O.8mg/mg ODN] 6hrs prior to 30min renal ischaemia, n=6) and A8
group (rats received As-ODN [2mglkg rat] + lipofectin [O.8mg/mg ODN] 8hrs prior to 30min renal
ischaemia, n=6) throughout the study.
3.8. Western Blot Analysis
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Figure 3..8.1A ICAM-l expression in renal medulla and cortex (Tm, Ie, A6 and A8)
These figures show the Western blots that depict the renal cortical and medullary ICAM-l expression of
the Ic group (rats received 30min of renal ischaemia, n=6), Tm group (rats that did not receive renal
ischaemia, n=6), A6 group (rats received As-OON [2mg/kg rat] + lipofectin [O.8mg/mg 00 ] 6hrs prior to
30min renal ischaemia, n=6) and A8 group (rats received As-ODN [2mg/kg rat] + 1ipofectin [O.8mg/mg
ODN] 8hrs prior to 30min renal ischaemia, n=6). The renal cortical and medullary ICAM-l expression of
A8 group's non-ischaemia insulted kidney (A8NIIK, n=6) is also shown.
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Figure 3..8.IB ICAM-I expression in renal medulla and cortex (Western blot densitometry assay
for Ie, Tm, A6 and A8)
The figure shows the results (Adjusted volume [AV) readings) of the Western blot densitometry assay
(mean ± SEM) on the renal cortical and medullary ICAM-l expression of the Ie group (rats received 30min
of renal ischaemia, n=6), Tm group (rats that did not receive renal ischaemia, n=6), A6 group (rats received
As-ODN [2mg/kg rat] + lipofectin [O.8mg/mg ODN] 6hrs prior to 30min renal ischaemia, n=6) and A8
group (rats received As-ODN [2mg/kg rat] + lipofectin [O.8mg/mg ODN] 8hrs prior to 30min renal
ischaemia, n=6). The densitometry assay result for the renal cortical and medullary ICAM-l expression of
A8 group's non-ischaemia insulted kidney (A8NIIK, n=6) is also shown.
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In the current phase, the tissue samples of the Ic and Tm groups were used tentatively as ischaemia
positive and normal control. The results have shown that the medullary expression of ICAM-l in the A6
group was found to be increased significantly as compared to the Tm group (about 5 folds of Tm's
expression, p<0.05) (Figure 3.8.1A and 3.8.1B). Although lower, the A6's ICAM-l expression was not
significantly different as compared to the Ic group. As for AS group, medullary ICAM-l expression was
depressed approximately 75% and 60% compared to the Ie (p<O.OI) and A6 (p<0.05) respectively. No
significant difference was found in between A8 and Tm (although AS's ICAM-l expression was slightly
elevated) (Figure 3.S.1A and 3.S.IB). The medullary ICAM-I expression in the right kidney (received no
ischaemia) of the A8 group's rats (A8 NIIK) was also found to be depressed (about 15% lower than the
Tm, however p> 0.05).
Meanwhile, the cortex expression of ICAM-lin A8 (both AS's ischaemic left kidney and A8
NIIK) were found to be significantly lower compared to the A6 group (p<0.05 and p<O.OI respectively).
Nevertheless, all groups that received lipofectin-As-ODN treatment exhibited significant elevation in
cortex ICAM-l expression when compared to the Ie and Tm groups (all p<OOOI). The cortex expression of
ICAM-I in A8 / A8 NIIK and A6 were also significantly higher when compared to respective medulla
ICAM-I expression (p<0.05) ((Figure 3.8.IA and 3.S.1B).
3.9 Discussion
In the Phase 2.1, the preliminary trial of the As-ODN on the progression of ischaemia-reperfusion
injury model suggested by Haller et al. was performed. The specific objectives of the study were to confirm
the significance of the role played by the ICAM-l upregulation in ischaemia reperfusion injury, and to
observe any possible improvement in post ischaemia renal physiology when the rats were treated with
antisense ODN to ICAM-lprior to ischaemia. At the same time, the time of the As-ODN administration
prior to ischaemia -reperfusion insult was tested so as to determine the optimal incubation period needed
for the administered As-ODN to enter the renal cells and exert its action.
Since an optimal time for OD administration has yet to be determined, the results of Ie group
and Tm group from Phase I study were used as ischaemia positive controls and baseline reference for all
the parameters assessed. A more proper baseline and ischaemia positive control is included in Phase 2.3
once the optimal ODN administration time was determined.
From the results, the arterial blood pressures of the A8 group (administered with As-ODN with
lipofectin 8hrs prior to ischaemia) and A6 group (administered with As-ODN with lipofectin 6hrs prior to
ischaemia) were found to be stable within the normal physiological range and resembled those of the Ie and
Tm groups over the course of study. These data indicated the absence of significant post surgical renal
function deterioration over the experimental period and also any possible renal haemodynamics and
functional changes due to changes in systemic circulation.
The RBF of both the A6 and A8 groups was found to be reduced significantly from baseline after
ischaemia, indicating the presence of an increase in a~eriolar vasculature resistance. The observation of
depression in GFR in the first 15 min of reperfusion in both groups also further suggested that the initial
RBF reduction was mainly due to the AAVR increase. Compared to the Ic group, the initial level of
reduction in both RBF and GFR of the A6 and A8 groups was much higher. This would suggest a more
potent increase in AAVR occurred in the A6 and A8 groups. The observed additional increase in AAVR
could be related to the action of ICAM-I, as the cortical expression of ICAM-I was found to be elevated
significantly in both groups (higher than that of Ie's), and an elevated ICAM-I protein expression was
proposed to be involved in causing the renal vascular resistance increase in Phase I. In this case, the
induction of the increased ICAM-l could have already taken place before ischaemia when considering the
significant increase in the ICAM-l expression level and the relatively low RBF basal values in A6 and A8
compared to Tm and Ie. Also, the elevation in cortical ICAM-I expression might be attributed to factors
other than ischaemia-reperfusion insult, as an increase in ICAM-I expression (above Ie group's expression
~- ~-~-~~-
level) was also found in the A8 NIIK cortex. Among the possible causative factors is the adverse or non
specific effects brought by either the ODNs or lipofectin. However, further evidence is needed in order to
determine the actual cause of the AAVR increase.
In the time period subsequent to the first 15 min of reperfusion, the rapid increase in GFR (which
significantly exceeded baseline at Ihr post ischaemia and persisted till the end of study, p<O.05) in the
presence of fluctuating but depressed RBF was found in the A6 group, indicating a mark increase in
EAYR. The primary cause of the observed EAYR increase in A6 could be similar to what was suggested in
Ic group (Phase 1, i.e. related to elevated ICAM-I expression), since the trend of the increase in GFR
closely resembled the Ie group post ischaemia (p>O.05) and the A6 medullary ICAM-l expression was also
significantly elevated (p<O.Ol compared to Tm, p>O.05 compared to Ic). This would indicate that either the
administered As-ODN has failed to exert its ameliorative property over ischaemic damage, or the
administration time of As-ODN at 6hrs prior to ischaemia insult is actually insufficient for the As-ODN to
take full function in suppressing the ICAM-l production. and also for the natural de~radation of the
existing endothelial expressed ICAM-I protein. Compared to the Ic group, the RBF reduction in the A6
group was significantly greater while the GFR of A6 persisted at similar/ slightly elevated level with Ie.
This would indicate the presence of additional EAVR increase in A6 during the later phase of reperfusion,
which may be caused by factors other than ischaemia insult. In this case, a toxicity effect caused by either
lipofectin or ODNs is again possible.
On the other hand, the GFR for the A8 group gradually returned to near baseline levels. The trends
of recovery can also be seen in RBF of the A8 group during the reperfusion period. Rather than an acute
increase in EAYR (which comes along with rapid increase of GFR in the presence of reduced RBF), the
gradual GFR increase in A8 would indicate recovery of glomerular filtration function in response to REF
recovery. Without doubt, the post ischaemia rapid increase in EAYR has been prevented in A8.
Along with the absence of a significant increase in EAVR, the A8 's medullary level ofICAM-l
expression was also found to be suppressed significantly to near baseline level. This would lead to the
following suggestions; that is, firstly, As-ODN for ICAM-l has exerted a positive inflllence in preventing
the acute post ischaemic increase ofEAYR, most probably via inhibition of the ICAM-l mRNA translation
and protein synthesis (as medullary ICAM-l expression was significantly depressed in both A8 and A8
NIIK), and thus the related series of renal efferent vasoconstriction events.
Secondly, the increased ICAM-l expression has indeed played a significant role in the
development of renal ischaemia reperfusion injury as attenuation of renal vascular endothelial ICAM-I
expression by As-ODN has significantly reduced the severity of the increase in EAYR in the post
ischaemia period.
Thirdly, an incubation period of at least 8 hr before ischaemia is required for the ICAM-I As-
ODN to exert its mRNA inhibitory effect, while waiting for the natural depletion of the already expressed
endothelial ICAM-I; as amelioration of the adverse renal physiological responses post ischaemia as well as
significant depression in ICAM-l synthesis was observed in A8 but not A6 !:TOUPS
Lastly, the additional exaggerated increase in EVAR increase and REF reduction observed in the
A6 group in the later phase of reperfusion was not found in the A8 group, indicating that these mentioned
abnormal renal physiological responses were probably not related to the ODN, but more likely to the
lipofectin. Also, the significant amelioration of EVAR increase and REF reduction specifically by As-ODN
for ICAM-I in the A8 group indicated that the proposed adverse effects brought by lipofectin against the
renal efferent vasculature had dissipated following the As-ODN treatment. This would suggest that the
lipofectin exerts it adverse effects mainly through aggravating the tissue inflammatory response, either
directly to enhance the ICAM-I production, or it exerts a toxic effect on the renal cell and thus indirectly
elevates the tissue inflammatory response (including ICAM-I production). However, the possibility that the
lipofectin may cause direct renal cell cytotoxicity, and thus increase the local production of
vasoconstrictors as well as the EAVR cannot be totally ruled out.
"In addition, the significant attenuation of the GFR and EAVR increase in the A8 group also
reflects that the As-ODN may have possibly attenuated the post-ischaemic local production of
vasoconstrictors and tubular swelling in the medullary region. This would suggest that either both local
production of vasoconstrictors and tubular swelling do not significantly contribute to the post ischaemia
EAVR increase, or the development of these pathological events were actually secondary to / largely
dependent on an ICAM-l mediated mechanism (as previously discussed in Phase 1 discussion). Either way,
it is evident that the increase in ICAM-l expression has indeed played a more significant role in the
development of renal ischaemia reperfusion injury compared to these factors.
On the other hand, in A8 group, although the REF and GFR recovered gradually in the later phase
of reperfusion, they were still significantly lower compared to the baseline at the end of the study. This
would probably relate to the increased ICAM-l expression in group A8's cortex (rather than due to the
ischaemia induced local release of vasoconstrictors). In group A8, although lower as compared to A6, the
cortex expression ofICAM-l was abnonnally and significantly higher as compared to the expression in Ie
and Tm group. It is suggested that the profound increase in cortex KAM-I expression h~s som~how
triggered additional afferent vasoconstriction and AAVR increase (which influences the GFR's full
recovery in this case). Here, the profound increase in cortex ICAM-l expression in A8 would indicate the
following:
a) Additional factor(s) that induced a significant increase in ICAM-l production was present in the
post-ischaemic kidney. In this case, the lipofectin is suggested to be the factor responsible. However,
further evidence is needed to prove this suggestion.
b) The As-ODN for ICAM-Iwas ineffective in reducing the elevated ICAM-l expression in the
cortex region. A possible explanation for this would be the cells of the renal cortex region (renal afferent
vasculature) did not take up As-ODN as efficiently as the cells of the renal medullary region (renal efferent
vasculature), thus leading to failure in total mRNA translation blockade of the As-ODN, especially in the
condition of excessive production of ICAM-l protein.
In the evaluation of the urine flow rate (UFR), absolute sodium excretion (AbsNa) and fractional
sodium excretion (FENa), the UFR, AbsNa and FENa of the A8 group was found to have recovered to
baseline level during the reperfusion. Whereas for the A6 group, post ischaemia levels of all 3 parameters
were significantly elevated above baseline, whereby the trend of elevations resembled those of the Ie group
(p>O.05). This indicated that the diuresis and natriuresis occurring in the Ic group post ischaemia due to
tubular damage and impaired tubular reabsorption was also found in the A6 group, but not in A8 group.
Again, the ICAM-l mediated EAVR increase and resultant prolonged medullary tissue hypoxia can again
be proposed to be responsible for the observed irreversible renal tubular damage and impaired tubular
reabsorption, as the use of As-ODN in A8 has effectively prevented this from happening
Furthermore, it was shown that the increased ICAM-l expression does playa significant role in
the development of renal ischaemia reperfusion injury (even when it is compared with other factors that
contribute to the injury). Meanwhile,. the atte~uation ?f renal vascular endothelial ICAM-l expression
through administration of As-OD for ICAM-l may significantly reduce the severity of the renal EAVR
increase post ischaemia, as well as ameliorating tubular damage and tubular reabsorption impairment.
Nevertheless, a minimal 8 hr incubation period before ischaemia is required for the As-ODN for ICAM-l
to exert its mRNA inhibitory effect, during which time there is a natural depletion of the already expressed
endothelial ICAM-I. Also, the renal cortex tissue was found to be less receptive towards the ameliorative
effect of the As-ODN for ICAM-l compared to the medullary tissue. The less efficient ODN uptake by the
cortex tissue was suggested to be a possible reason.
The present findings have also shown that the use of lipofectin may exacerbate post ischaemia
renal tissue injury (i.e. lipofectin was suspected to cause increase in EAVR and AAVR during reperfusion
period); possibly via enhancement of the renal tissue inflammatory response. Nevertheless, further
evidence is needed to confirm this suggestion.
I(,
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4. Overall view
In the current study, we have found that a 30 minute ischaemia-reperfusion insult to the kidney
could cause significant disturbances to the renal physiology and function, whereby in the initial
development of these distortions (first.3 hours post ischaemia), it was suggested that the changes could be
attributed to the increase in afferent and efferent arteriolar vascular resistance (AAVRJ EAVR), rather than
extensive renal tissue damage by leukocytes (as leukocyte infiltration and related inflammatory damage of
tissue were not clearly evident in the histological study). The elevated ICAM-I expression in the kidney
was proposed to be responsible for the post ischaemic increase of AAVRJ EAVR, as administration of As-
ODN to ICAM-l (but not the control Rv-ODN) significantly reduced renal ICAM-l expression and at the
same time ameliorated the AAVRJ EAVR increase.
The simultaneous amelioration of renal physiological and functional distortion along with the
reduction of renal ICAM-l expression after As-OD administration also underscore the significance of the
additional role played by ICAM-l (other than mediating leukocyte infiltration) in the initial development
of renal ischaemia-reperfusion injury, and prove the effectiveness of ICAM-l in ameliorating ischaemia-
reperfusion injury.
A further observation was that lipofectin was found to cause an adverse distortion to renal
physiology and function, and thus it is proposed to be unsuitable for use as an in vivo transfecting agent for
As-ODN delivery. In our study, we have developed an alternative double dose As-ODN administration
protocol which does not involve the use of lipofectin and found to be effective in ameliorating the renal
ischaemia-reperfusion injury, collectively thus suggesting that As-ODN delivery to the kidney can be
performed even in the absence of transfecting agent.
Within the limitation of this study, the As-ODN to ICAM-l was found to be capable of reducing
the renal physiological and function deterioration after ischaemia, and thus it would seeJTl to be an effective
mean of ameliorating renal ischaemia reperfusion injury. However, the use of the As-ODN is still limited
I
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as a prophylactic treatment (e.g. prior to cardiac surgery or renal transplantation), as the present methods
employed were still unable to deliver As-ODN rapidly into the kidney. Thus, a better method that can
deliver the As-ODN into the target tissue needs to be developed so that the As-ODN can be employed for
therapeutic purposes effectively.
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